GSK teams up with LTZ Therapeutics to launch next-generation cancer therapies
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The formulation is backed by over 80 clinical trials and 200 scientific publications
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Subscribe To Our Newsletter & Stay Updated